德谷胰岛素——一种超长效基础胰岛素类似物研究进展

摘要

Insulin degludec (Ideg) has unique molecular structure which could form multi-hexamers (drug depot) after subcutaneous injection, resulting in an ultra-long effect (half life of Ideg> 24h), a consistent and flat pharmacokinetic profile at steady state, and the consistently low within-subject variability of pharmacodynamics. From the clinical trial results available, Ideg is safe with reduced rate of hypoglycemic events and is reliable with stable glycemic control.%德谷胰岛素分子结构独特,在皮下注射部位形成多六聚体结构的药物储库,从而发挥超长药效(＞24h),是一种新型超长效胰岛素类似物.德谷胰岛素的药动学曲线平稳,药效学变异性小.临床研究结果显示德谷胰岛素能够有效的控制血糖,同时降低了治疗期间低血糖事件的发生.